


08-10-05

1fw



Dkt. No. 29248/18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Erik Buntinx

Appl. No. : 10/725,965

Filed : December 2, 2003

For : METHOD OF TREATING MENTAL DISORDERS USING OF
D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR
PARTIAL AGONISTS

Group Art : 1617

Examiner : Jennifer M. Kim

Customer No. : 1912

"Express Mail" mailing label No.	EV 725786128 US
Date of Deposit:	August 9, 2005
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Alan D. Miller
Signature:	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the references that are listed on Form PTO/SB/08A-B (6 pages) attached hereto along with copies of the six foreign patent documents and 34 non-patent literature documents. All of these references, with the exception of two that are discussed below, were cited in European Search Reports issued in connection with related European Patent Application Nos. EP 03 44 7279.5, EP 04 44 7066.4, and/or EP 04 02 5035.9, and/or in an International Search Report issued in connection with related PCT Patent Application No. PCT/BE2004/000172. Copies of these six Search Reports are also attached hereto. Finally, also listed are the publications

Applicants: Erik Buntinx
Appl'n. No.:10/725,965
Filed: December 2, 2003
Page 2


of two related later-filed U.S. Patent Applications by applicant. A third later-filed application by applicant, U.S. Patent Application No. 10/984,683, has not yet published.

Applicants are submitting the subject Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required in connection with the submission of this Information Disclosure Statement or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,
AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: August 9, 2005
New York, New York

By 
Alan D. Miller, Reg. No. 42,889



(Use as many sheets as necessary)

Sheet	1	of	6
-------	---	----	---

Complete if Known

Application Number	10/725,965
Filing Date	December 2, 2003
First Named Inventor	Erik Buntinx
Art Unit	1617
Examiner Name	Jennifer M. Kim
Attorney Docket Number	29248/18

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	4	WO 01/98298 A	12-27-2001	H. LUNDBECK A/S		
	5	WO 98/43646 A	10-08-1998	AKZO NOBEL N.V.		
	6	WO 98/11897 A	03-26-1998	ELI LILLY AND COMPANY		
	7	WO 00/64441 A	11-02-2000	RESPIRATORIUS AB		
	8	WO 02/051833 A	07-04-2002	E.C.L.		

Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Complete if Known

(Use as many sheets as necessary)

Sheet	2	of	6
-------	---	----	---

Application Number	10/725,965
Filing Date	December 2, 2003
First Named Inventor	Erik Buntinx
Art Unit	1617
Examiner Name	Jennifer M. Kim
Attorney Docket Number	29248/18

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	1 ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	9	DE 40 39 631 A	06-17-1992	Troponwerke GmbH &		
				Co KG		

Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/725,965
				Filing Date	December 2, 2003
				First Named Inventor	Erik Buntinx
				Art Unit	1617
				Examiner Name	Jennifer M. Kim
Sheet	3	of	6	Attorney Docket Number	29248/18

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	10	SCHINDLER T et al., entitled "Palliative medical management in anxiety and depression," Zeitschrift Fur Allgemeinmedizin, Vol. 74, No. 21, November 5, 1998, pp. 973-978.		
	11	VOLMAT R et al., entitled "The treatment of depressions by Cledial. Evolution and clinical state and handwriting," Psychologie Medicale, Vol. 18, No. 10, 1986, pp. 1615-1622.		
	12	FOUKS et al., entitled "Treatment of character disorders with a new butyrophenone: R. 3345 or pipamperone," Annales Medico-Psychologiques, Vol. 124, No. 5, 1966, pp. 677-681.		
	13	SQUELART P et al., entitled "Pipamperone (Dipiperon), a useful sedative neuroleptic drug in troublesome chronic psychotic patients," Acta Psychiatrica Belgica, Vol. 77, No. 2, March 1977, pp. 284-293.		
	14	KOCH H J et al., entitled "Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapinr and tiapride," International Journal of Clinical Practice, Vol. 57, No. 2, March 2003, pp. 147-149.		
	15	DIEBOLD K et al., entitled "Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?" Pharmacopsychiatry, 1998, 31/2, pp. 60-67.		
	16	GROZINGER M et al., entitled "Melperone is an inhibitor of the CYP2D6 catalyzed 0-demethylation of venlafaxine," Pharmacopsychiatry, Vol. 36, No. 1, January 3003, pp. 3-6.		
	17	PERUGI G et al., entitled "Effectiveness of Adjunctive Gabapentin in Resistant Bipolar Disorder: Is it due to anxious-alcohol abuse comorbidity?" Journal of clinical Psychopharmacology, Vol. 22, No. 6, 2002, pp. 584-591.		
	18	WIELING W et al., entitled "Initial orthostatic hypotension as a cause of recurrent syncope: A case report," Clinical Autonomic Research, Vol. 11, No. 4, 2001, pp. 269-270.		
	19	DATABASE PHARMAPROJECTS 'ONLINE! PJB Publications Ltd., December 1999. Caesar accession no. 1498		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/725,965
				Filing Date	December 2, 2003
				First Named Inventor	Erik Buntinx
				Art Unit	1617
				Examiner Name	Jennifer M. Kim
Sheet	4	of	6	Attorney Docket Number	29248/18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	20	ADLER L et al., entitled "Praxis Der Stationaeren Akutbehandlung Von Manien Retrospektive Vergleichsuntersuchung An Je 100 Patienten Zweier Psychiatrischer Sentren Practice of In-Patient Acute Treatment of Manias," Fortschritte Der Neurologie Psychiatrie, Stuttgart, Vol. 62, No. 12, 1994, pp. 479-488.	
	21	ANSOMS C et al., entitled "Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamerone (Dipiperon)," Acta Psychiatrica Scandinavica, Vol. 55, No. 2, February 1977, pp. 116-122.	
	22	LEYSEN J E et al., entitled "Receptor interactions of new antipsychotics: Relation to Pharmacodynamic and Clinical Effects," International Journal of Psychiatry in Clinical Practice, Vol. 2, No. 1, 1998, pp. S03-S17.	
	23	VANHOENACKER P et al., entitled "Efficient Expression of the Human Dopamine D4.2 Receptor: Positive Influence of Pipamperone on Expression Levels," Abstracts of the Society for Neuroscience, Vol. 26, No. 1/2, 2000.	
	24	SCHOTTE A et al., entitled "Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding," Psychopharmacology, Vol. 124, No. 1-2, 1996, pp. 57-73.	
	25	WOGGON B, entitled "Pharmakologische depressionbehandlung pharmacological treatment of depression," Therapeutische Umschau, Vol. 57, No. 2, 2000, pp. 81-89.	
	26	VAN DE VIJVER DAMC et al., entitled "Antipsychotics and Parkinson's disease: Association with disease and drug choice during the first 5 years of antiparkinsonian durg treatment," Eur J Clin Pharmacology, Vol 58, 2002, pp. 157-161.	
	27	JOVIC NI et al., entitled "Phenomenology and treatment of delirium in Alzheimer's disease!" Revue Medicale De La Suisse Romande, Vol. 117, No. 9, September 1997, pp. 655-658.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/725,965		
		Filing Date	December 2, 2003		
		First Named Inventor	Erik Buntinx		
		Art Unit	1617		
		Examiner Name	Jennifer M. Kim		
Sheet	5	of	6	Attorney Docket Number	29248/18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	28	ENGELBORGH S et al., entitled "Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease," Neurochemical Research, Vol. 28, No. 8, August 2003, pp. 1145-1150.	
	29	NEWMAN-TANCREDIT A et al., [35S]-guanosine-5'-0-(3-thio) triphosphate binding as a measure of efficacy at human recombinant dopamine D-4.4 receptors: Actions of antiparkinsonian and antipsychotic agents. Journal of Pharmacology and Experimental Therapeutics, Vol. 282, No. 1, 1997 pp. 181-191.	
	30	TARAZI F I et al., entitled "Role of dopamine D4 receptors in neuropsychiatric disorders," Journal of Neurochemistry, Vol. 81, No. Supplement 1, June 2002, p. 33. Abstract	
	31	TARAZI F I et al., entitled "Dopamine D4 Receptors: Significance for Molecular Psychiatry at the Millennium," Molecular Psychiatry, Vol. 4, No. 6, November 1999, pp. 529-538.	
	32	LEOPOLD N A, entitled "Risperidone treatment of drug-related psychosis in patients with parkinsonism," Movement Disorders. Vol. 15, No. 2, March 2000, pp. 301-304.	
	33	HADJ TAHAR A et al., entitled "Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys," European Journal of Pharmacology, Vol. 399, No. 2-3, July 7, 2000, pp. 183-186.	
	34	ZESIEWICZ TA et al., entitled "Clozapine withdrawal symptoms in a Parkinson's disease patient," Movement Disorders: Vol. 17, No. 6, November 2002, pp. 1365-1367.	
	35	FALTRACO F et al., Aktuelle Therapiemoglichkeiten der Alzheimer Demenz (Current Therapeutical Strategies in Dementia), Neurol Rehabil 2003; 9 (1), pp.15-22.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/725,965
				Filing Date	December 2, 2003
				First Named Inventor	Erik Buntinx
				Art Unit	1617
				Examiner Name	Jennifer M. Kim
Sheet	6	of	6	Attorney Docket Number	29248/18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	36	ETCHEPAREBORDA M C, entitled "Neurocognitive and pharmacological approach to specific learning disorders," Database Medline "Online", US National Library of Medicine, February 1999, and Revista De Neurologia, Vol. 28, Suppl. 2, February 1999, pp. S81-S93, Abstract.	
	37	STAHL S M et al., entitled "Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease," Current Medical Research and Opinion 2004, Vol. 20, No. 4, 2004, pp. 517-524.	
	38	MENESES A et al., entitled "Are 5-HT (1B/1D) and 5-HT (2A/2B/2C) receptors involved in learning and memory processes?" IDrugs 1999, Vol. 2, No. 8, 1999, pp. 796-801.	
	39	WIRZ-JUSTICE A et al., entitled "Haloperidol disrupts, clozapine reinstates the circadian rest-activity cycle in a patient with early-onset Alzheimer disease," Alzheimer Disease and Associated Disorders, Vol. 14, No. 4, 2000, pp. 212-215.	
	40	FAHS H et al., entitled "Thymoregulateurs Dans L'Agitation et les Troubles Du Comportement Chez le Sujet Dement a Propos de Huit Cas, Anticonvulsivants and Aggressive Behaviors in Alzheimer's Disease. Eight Cases Reports," L'Encephale Vol. 25, No. 2, 1999, pp. 169-174.	
	41	WERTH E et al., entitled "Decline in long-term circadian rest-activity cycle organization in a patient with dementia," Journal of Geriatric Psychiatry and Neurology, Vol. 15, No. 1, April 2002, pp. 55-59.	
	42	MELTZER HY et al., entitled "Plasma clozapine levels and the treatment of L-Dopa-induced psychosis in Parkinson's disease. A high potency effect of clozapine," Neuropsychopharmacology, Vol. 12, No. 1, 1995, pp. 39-45.	
	43	MUNCHAU A et al., entitled "Pharmacological Treatment of Parkinson's Disease," Postgraduate Medical Journal, Vol. 76, October 2000, pp. 602-610.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.